Alexander Ngwube
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alexander Ngwube has a total of 201 co-authors. Here are the top co-authors by number of shared publications:
Dana Salzberg
Division of Hematology and Oncology, Phoenix Children's, Phoenix, AZ
14 shared publicationsKristen Beebe
Phoenix Children's Hospital Center for Cancer and Blood Disorders Phoenix Arizona USA
12 shared publicationsHolly Miller
The University of Arizona College of Medicine Department of Child Health Phoenix Arizona USA
10 shared publicationsCourtney Campbell
Phoenix Children's Hospital Center for Cancer and Blood Disorders Phoenix Arizona USA
9 shared publicationsRoberta Adams
The University of Arizona College of Medicine – Phoenix, Phoenix, Arizona, USA
7 shared publicationsCharlotte Schwalbach
Phoenix Children's Hospital Center for Cancer and Blood Disorders Phoenix Arizona USA
6 shared publications
Latest Publications
- 18 November 2026
- Published by Wiley in Pediatric Blood & Cancer
Total Serum IgG Is a Poor Surrogate for Pneumococcal Protection Following Hematopoietic Stem Cell Transplantation in Pediatric Sickle Cell Disease
Background: Children with sickle cell disease (SCD) have functional asplenia and a higher risk of invasive pneumococcal disease. While allogeneic hematopoietic stem cell transplantation (HSCT) is curative, post‐transplant immune reconstitution is heterogeneous. Total serum immunoglobulin G (IgG) is widely used to gauge humoral recovery yet may not reflect pneumococcal serotype‐specific seroprotection. Methods: We performed a single‐center retrospective cohort study of pediatric patients with SCD who underwent myeloablative matched sibling donor HSCT at Texas Children's Hospital between 2005 and 2024 and obtained pneumococcal serotype‐specific antibody titers at approximately 1 year. Seroprotection was defined as an antibody concentration ≥1.3 µg/mL in ≥70% of 14 tested serotypes. Longitudinal total IgG, IgA, IgM, tetanus titers, and lymphocyte subsets (CD3 + , CD4 + , CD8 + , CD19 + ) were analyzed. Receiver operating characteristic (ROC) analysis and penalized multivariable logistic regression were performed ( n = 51). Results: Of 51 patients, 32 (62.7%) achieved pneumococcal serotype‐specific protection at approximately 1 year. Total IgG correlated weakly with protection at all time points ( r = 0.28–0.38). Day +365 total IgG did not differ between protected and unprotected patients ( p = 0.134); at commonly used thresholds between 400 and 600 mg/dL, sensitivity was 97%, but specificity was 0%, and all unprotected patients exceeded 600 mg/dL. Day +365 IgG showed limited discrimination (AUC 0.63). Broad quantitative lymphocyte subsets were also not significantly correlated with the proportion of protective pneumococcal serotypes. No invasive pneumococcal disease occurred during follow‐up. Conclusions: Normal total serum IgG does not reliably identify pneumococcal serotype‐specific seroprotection after HSCT in pediatric SCD. Serotype‐specific antibody assessment provides information not captured by total IgG alone.
- 18 November 2026
- Published by Wiley in Pediatric Blood & Cancer
Total Serum IgG Is a Poor Surrogate for Pneumococcal Protection Following Hematopoietic Stem Cell Transplantation in Pediatric Sickle Cell Disease
Background: Children with sickle cell disease (SCD) have functional asplenia and a higher risk of invasive pneumococcal disease. While allogeneic hematopoietic stem cell transplantation (HSCT) is curative, post‐transplant immune reconstitution is heterogeneous. Total serum immunoglobulin G (IgG) is widely used to gauge humoral recovery yet may not reflect pneumococcal serotype‐specific seroprotection. Methods: We performed a single‐center retrospective cohort study of pediatric patients with SCD who underwent myeloablative matched sibling donor HSCT at Texas Children's Hospital between 2005 and 2024 and obtained pneumococcal serotype‐specific antibody titers at approximately 1 year. Seroprotection was defined as an antibody concentration ≥1.3 µg/mL in ≥70% of 14 tested serotypes. Longitudinal total IgG, IgA, IgM, tetanus titers, and lymphocyte subsets (CD3 + , CD4 + , CD8 + , CD19 + ) were analyzed. Receiver operating characteristic (ROC) analysis and penalized multivariable logistic regression were performed ( n = 51). Results: Of 51 patients, 32 (62.7%) achieved pneumococcal serotype‐specific protection at approximately 1 year. Total IgG correlated weakly with protection at all time points ( r = 0.28–0.38). Day +365 total IgG did not differ between protected and unprotected patients ( p = 0.134); at commonly used thresholds between 400 and 600 mg/dL, sensitivity was 97%, but specificity was 0%, and all unprotected patients exceeded 600 mg/dL. Day +365 IgG showed limited discrimination (AUC 0.63). Broad quantitative lymphocyte subsets were also not significantly correlated with the proportion of protective pneumococcal serotypes. No invasive pneumococcal disease occurred during follow‐up. Conclusions: Normal total serum IgG does not reliably identify pneumococcal serotype‐specific seroprotection after HSCT in pediatric SCD. Serotype‐specific antibody assessment provides information not captured by total IgG alone.
- Open Access
- 1 October 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (12) , 3082-3086
Radiation‐Free Haploidentical Transplantation With PTCy and Extended Abatacept in Pediatric Nonmalignant Disorders
- 1 October 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (12) , 3082-3086
Open AccessRadiation‐Free Haploidentical Transplantation With PTCy and Extended Abatacept in Pediatric Nonmalignant Disorders
- Open Access
- 20 July 2026
- Published by Elsevier in Blood Immunology & Cellular Therapy
- Vol. 2 (3)
Referral variability and provider preparedness for pediatric sickle cell gene therapy: a national survey
- 20 July 2026
- Published by Elsevier in Blood Immunology & Cellular Therapy
- Vol. 2 (3)
Open AccessReferral variability and provider preparedness for pediatric sickle cell gene therapy: a national survey
- Open Access
- 19 June 2026
- Published by Wiley in European Journal of Haematology
- Vol. 117 (4) , 1052-1060
Project Sickle Cure: A Prospective, International Observational Study of Hematopoietic Cell Transplantation for Sickle Cell Disease
Background: Sickle cell disease (SCD) is a chronic and life‐limiting hemoglobin and systemic vascular disease. While over 1000 people have undergone hematopoietic cell transplantation (HCT) over the last 40 years, long‐term disease‐specific and health‐related quality of life data are lacking. The American Society of Hematology 2021 Guidelines for SCD emphasized the need for more detailed registry data to inform patients and providers with decision‐making and practice recommendations. Procedures: In January 2021, the Sickle Cell Transplant Advocacy and Research Alliance (STAR) launched Project Sickle Cure (PSC). This multi‐center, prospective study of patients who have undergone HCT for SCD includes baseline demographics and SCD‐specific post‐HCT outcomes, serial neurocognitive testing, health‐related quality of life measures, health equity evaluations, a neuroimaging bank, detailed evaluation of neurologic status pre‐ and post‐transplant, and chronic pain evaluation. A biorepository is in the planning stage of development. Results: As of November 2025, 115 participants have enrolled at 18 STAR sites with enrollment ongoing. Conclusions: PSC is a STAR prospective study which will address a major gap in our understanding of outcomes post‐HCT specific to SCD. WeDecide, a larger study comparing HCT health‐related quality of life outcomes to those who receive non‐transplant disease modifying therapy (NT‐DMT) is in development, and PSC will provide the HCT comparator data. These data will also be highly relevant as other curative and transformative therapies, such as gene therapy, become more widely used.
- 19 June 2026
- Published by Wiley in European Journal of Haematology
- Vol. 117 (4) , 1052-1060
Open AccessProject Sickle Cure: A Prospective, International Observational Study of Hematopoietic Cell Transplantation for Sickle Cell Disease
Background: Sickle cell disease (SCD) is a chronic and life‐limiting hemoglobin and systemic vascular disease. While over 1000 people have undergone hematopoietic cell transplantation (HCT) over the last 40 years, long‐term disease‐specific and health‐related quality of life data are lacking. The American Society of Hematology 2021 Guidelines for SCD emphasized the need for more detailed registry data to inform patients and providers with decision‐making and practice recommendations. Procedures: In January 2021, the Sickle Cell Transplant Advocacy and Research Alliance (STAR) launched Project Sickle Cure (PSC). This multi‐center, prospective study of patients who have undergone HCT for SCD includes baseline demographics and SCD‐specific post‐HCT outcomes, serial neurocognitive testing, health‐related quality of life measures, health equity evaluations, a neuroimaging bank, detailed evaluation of neurologic status pre‐ and post‐transplant, and chronic pain evaluation. A biorepository is in the planning stage of development. Results: As of November 2025, 115 participants have enrolled at 18 STAR sites with enrollment ongoing. Conclusions: PSC is a STAR prospective study which will address a major gap in our understanding of outcomes post‐HCT specific to SCD. WeDecide, a larger study comparing HCT health‐related quality of life outcomes to those who receive non‐transplant disease modifying therapy (NT‐DMT) is in development, and PSC will provide the HCT comparator data. These data will also be highly relevant as other curative and transformative therapies, such as gene therapy, become more widely used.
- Open Access
- 29 January 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (3) , 618-619
Rules, risks, and reality: rethinking gene therapy eligibility
- 29 January 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (3) , 618-619
Open AccessRules, risks, and reality: rethinking gene therapy eligibility
- Open Access
- 19 June 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 31 (10) , 826.e1-826.e10
Impact of Abatacept Inclusive Graft-Versus-Host Disease Prophylaxis in Pediatric Stem Cell Transplantation for Hemoglobinopathy
- 19 June 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 31 (10) , 826.e1-826.e10
Open AccessImpact of Abatacept Inclusive Graft-Versus-Host Disease Prophylaxis in Pediatric Stem Cell Transplantation for Hemoglobinopathy
- Open Access
- 14 December 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 31 (2) , 97.e1-97.e11
A Retrospective Analysis of Fresh versus Cryopreserved Allogenic Bone Marrow Transplant within a Pediatric Population: A Change in Practice Due to the COVID-19 Pandemic
- 14 December 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 31 (2) , 97.e1-97.e11
Open AccessA Retrospective Analysis of Fresh versus Cryopreserved Allogenic Bone Marrow Transplant within a Pediatric Population: A Change in Practice Due to the COVID-19 Pandemic
- 14 December 2023
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (2) , 288-290
Abatacept treatment for autoimmune hemolytic anemia occurring post hematopoietic stem cell transplantation
- 14 December 2023
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (2) , 288-290
Abatacept treatment for autoimmune hemolytic anemia occurring post hematopoietic stem cell transplantation
- 19 June 2023
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (9) , e30493
Investigating racial disparities in quality‐of‐life years after pediatric hematopoietic stem cell transplant
Background: While racial disparities in the clinical outcomes of hematopoietic stem cell transplant (HSCT) patients have been explored, racial disparities in quality of life (QoL) during the re‐adjustment phase after transplant are yet to be investigated in pediatric patients. The objective of this study was to examine the role of patient race in QoL at least 2 years after pediatric HSCT.Procedure: We conducted a retrospective chart review of patients under 21 years of age at diagnosis who received an allogeneic transplant at our institution between January 2007 and December 2017. Patient QoL was assessed using the Pediatric Quality‐of‐Life Inventory Generic Score Scales (PedsQL TM 4.0) at least 2 years post transplant. Patient demographic, treatment, and transplant outcome data were obtained for subsequent analysis, where patient race was categorized as either Black, White, Hispanic, or Native American.Results: Data were collected on 86 pediatric patients who underwent HSCT. Forty patients (46.5%) were non‐Hispanic White, 29 (33.7%) Hispanic, 10 (11.6%) Black, and seven (8.1%) Native American. Where preliminary analyses indicated a difference in QoL by patient race, there were no significant differences in physical, emotional, social, and school functioning by patient race after adjusting for transplant characteristics (age at transplant, sex, diagnosis, donor type, and conditioning regimen) and determinants of socioeconomic status (insurance type, estimated household income).Conclusions: Pediatric patients had comparable QoL, regardless of race, at a median of 3 years after HSCT in our study cohort.
- 19 June 2023
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (9) , e30493
Investigating racial disparities in quality‐of‐life years after pediatric hematopoietic stem cell transplant
Background: While racial disparities in the clinical outcomes of hematopoietic stem cell transplant (HSCT) patients have been explored, racial disparities in quality of life (QoL) during the re‐adjustment phase after transplant are yet to be investigated in pediatric patients. The objective of this study was to examine the role of patient race in QoL at least 2 years after pediatric HSCT.Procedure: We conducted a retrospective chart review of patients under 21 years of age at diagnosis who received an allogeneic transplant at our institution between January 2007 and December 2017. Patient QoL was assessed using the Pediatric Quality‐of‐Life Inventory Generic Score Scales (PedsQL TM 4.0) at least 2 years post transplant. Patient demographic, treatment, and transplant outcome data were obtained for subsequent analysis, where patient race was categorized as either Black, White, Hispanic, or Native American.Results: Data were collected on 86 pediatric patients who underwent HSCT. Forty patients (46.5%) were non‐Hispanic White, 29 (33.7%) Hispanic, 10 (11.6%) Black, and seven (8.1%) Native American. Where preliminary analyses indicated a difference in QoL by patient race, there were no significant differences in physical, emotional, social, and school functioning by patient race after adjusting for transplant characteristics (age at transplant, sex, diagnosis, donor type, and conditioning regimen) and determinants of socioeconomic status (insurance type, estimated household income).Conclusions: Pediatric patients had comparable QoL, regardless of race, at a median of 3 years after HSCT in our study cohort.
- 11 May 2023
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 40 (7) , 1-5
Pre-hematopoietic stem cell transplantation lung computed tomography is not an alternative to PFT for pediatric patients with sickle cell disease
Pulmonary function test (PFT) plays a vital role in risk stratification before allogenic hematopoietic stem cell transplantation (HSCT) and is a useful tool for predicting and preventing unfavorabl...
- 11 May 2023
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 40 (7) , 1-5
Pre-hematopoietic stem cell transplantation lung computed tomography is not an alternative to PFT for pediatric patients with sickle cell disease
Pulmonary function test (PFT) plays a vital role in risk stratification before allogenic hematopoietic stem cell transplantation (HSCT) and is a useful tool for predicting and preventing unfavorabl...